Fusion Proteins: Aflibercept (VEGF Trap-Eye) - PubMed
Aflibercept (VEGF Trap-Eye) is a soluble fusion protein which combines ligand-binding elements taken from the extracellular components of VEGF receptor (VEGFR)-1 and VEGFR-2 fused to the Fc portion of IgG. This protein contains all human amino-acid sequences, which minimizes the potential for immunogenicity in human patients.
Vascular Endothelial Growth Factor Trap-Eye for Macular
2011年9月24日 · Ocular neovascularization was not observed in eyes receiving anti-VEGF therapy. The VEGF Trap-Eye treatment was well tolerated and was associated with a low incidence of ocular adverse events. With its generally favorable safety profile, VEGF Trap-Eye may offer an effective treatment option for eyes with central retinal vein occlusion.
Review Targeting VEGF in eye neovascularization: What's new?: A ...
2016年1月1日 · Aflibercept, or VEGF Trap-Eye, is a fully human recombinant protein of 115 kDa consisting of key binding domains from VEGF receptor (VEGFR)-1 and VEGFR-2 fused to an IgG Fc fragment [21]. It acts as a soluble decoy receptor recognizing and neutralizing all VEGF-A isoforms, with the establishment of a tighter binding than the native receptors.
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related …
2012年7月26日 · Intravitreal aflibercept injection (IAI) (previously known in the scientific literature as VEGF Trap-Eye, Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) is a soluble decoy receptor fusion protein 16,17 that is specifically purified and formulated for …
VEGF Trap-Eye for the treatment of neovascular age-related
VEGF Trap-Eye is a novel anti-VEGF therapy, with Phase I and II trial data indicating safety, tolerability and efficacy for the treatment of neovascular AMD. Two Phase III clinical trials (VIEW-1 and VIEW-2) comparing VEGF Trap-Eye to ranibizumab are …
A Phase I Study of Intravitreal Vascular Endothelial
To determine the safety, tolerability, maximum tolerated dose, and bioactivity of an intravitreal injection of vascular endothelial growth factor (VEGF) Trap-Eye, a fusion protein of binding domains from human VEGF receptors 1 and 2 with human immunoglobulin-G Fc that binds VEGF family members, in patients with neovascular age-related macular ...
Aflibercept: a Potent Vascular Endothelial Growth Factor ... - Springer
2012年5月29日 · VEGF Trap-Eye has enhanced the treatment options currently available for the management of neovascular AMD. The comparable efficacy of VEGF Trap-Eye (to other anti-VEGF agents) coupled with its longer dosing interval may decrease the number of annual office visits for patients with AMD and their caregivers.
(PDF) VEGF Trap-Eye for the treatment of neovascular age-related ...
2009年8月1日 · VEGF Trap-Eye is a novel anti-VEGF therapy, with Phase I and II trial data indicating safety, tolerability and efficacy for the treatment of neovascular AMD. Two Phase III clinical trials (VIEW-1...
Vascular endothelial growth factor trap-eye and trap …
Aflibercept/VEGF trap-eye (VTE) is a soluble fusion protein, which combines ligand-binding elements taken from the extracellular components of VEGF receptors 1 and 2 fused to the Fc portion of IgG. This protein contains all human amino acid sequences, which minimizes the potential for immunogenicity in human patients.
Afliber-cept, previously known as VEGF Trap Eye, is a fusion protein of VEGF receptors 1 and 2 and a treatment for several retinal diseases related to angiogenesis. It has firmly joined ranibizumab and bevacizumab as an important thera-peutic option in the management of neovascular AMD-, DME- and RVO-associated macular edema.